SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorGozalbo-Rovira, Roberto-
Autor(es): dc.creatorGimenez, Estela-
Autor(es): dc.creatorLatorre, Víctor-
Autor(es): dc.creatorFrancés-Gómez, Clara-
Autor(es): dc.creatorAlbert, Eliseo-
Autor(es): dc.creatorBuesa, Javier-
Autor(es): dc.creatorMarina, Alberto-
Autor(es): dc.creatorBlasco, María Luisa-
Autor(es): dc.creatorSignes-Costa, Jaime-
Autor(es): dc.creatorRodríguez-Díaz, Jesús-
Autor(es): dc.creatorGeller, Ron-
Autor(es): dc.creatorNavarro, David-
Data de aceite: dc.date.accessioned2026-02-09T11:10:20Z-
Data de disponibilização: dc.date.available2026-02-09T11:10:20Z-
Data de envio: dc.date.issued2020-10-08-
Data de envio: dc.date.issued2020-10-08-
Data de envio: dc.date.issued2020-10-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/43359-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S138665322030353X-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1135246-
Descrição: dc.descriptionBackground The involvement of SARS-CoV-2 antibodies in mediating immunopathogenetic events in COVID-19 patients has been suggested. By using several experimental approaches, we investigated the potential association between SARS-CoV-2 IgGs recognizing the spike (S) protein receptor-binding domain (RBD), neutralizing antibodies (NtAb) targeting S, and COVID-19 severity. Patients and methods This unicenter, retrospective, observational study included 51 hospitalized patients (24 at the intensive care unit; ICU). A total of 93 sera from these patients collected at different time points from the onset of symptoms were analyzed. SARS-CoV-2 RBD IgGs were quantitated by ELISA and NtAb50 titers were measured in a GFP reporterbased pseudotyped virus platform. Demographic and clinical data, complete blood counts, as well as serum levels of ferritin, Dimer-D, C reactive protein (CRP), lactose dehydrogenase (LDH), and interleukin-6 (IL-6) were retrieved from clinical charts. Results The overall correlation between levels of both antibody measurements was good (Rho = 0.82; P = 0 < 0.001). SARS-CoV-2 RBD IgG and NtAb50 levels in sera collected up to day 30 after the onset of symptoms were comparable between ICU and non-ICU patients (P=>0.1). Four ICU patients died; two of these achieved NtAb50 titers ≥1/160 while the other two exhibited a 1/80 titer. Very weak (Rho=>0.0–<0.2) or weak (Rho=>0.2–<0.4) correlations were observed between anti-RBD IgGs, NtAb50, and serum levels pro-inflammatory biomarkers. Conclusions The data presented herein do not support an association between SARS-CoV-2 RBD IgG or NtAb50 levels and COVID-19 severity.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceJournal of Clinical Virology-
Palavras-chave: dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectNeutralizing antibodies-
Palavras-chave: dc.subjectInflammatory biomarkers-
Título: dc.titleSARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.